Search Results - Clayton D. Knox

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

    A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML) by Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop M. Kantarjian, Amy O. Johnson‐Levonas, Craig Fancourt, Raymond W. Lam, Mary Jones, Clayton D. Knox, Shelonitda Rose, Payal Patel, Raoul Tibes

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

    Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors by Andrew J. Wagner, Udai Banerji, Amit Mahipal, Neeta Somaiah, Heather A. Hirsch, Craig Fancourt, Amy O. Johnson‐Levonas, Raymond W. Lam, Amy Meister, Giuseppe Lo Russo, Clayton D. Knox, Shelonitda Rose, David S. Hong

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: